Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in mild Alzheimer's dementia
NL-OMON43600Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of osoresnontrine in Alzheimer's disease (AD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in Neuropsychological Test Battery total z-score at 12 weeks. Started Jan 2015; status: active, not recruiting.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON43600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43600.